Bluebird Bio (BLUE) won’t be selling the world’s most expensive drug. The second priciest? Yup.
Zynteglo, the one-and-done gene therapy for beta thalassemia newly approved in Europe, will carry a price tag of $1.8 million, Bluebird announced Friday. Only Zolgensma, the Novartis (NVS) gene therapy for spinal muscular atrophy, is priced higher, at $2.1 million.